Peptide agoniste des récepteurs mélanocortines.
PT-141 (Bremelanotide) is a synthetic melanocortin peptide that activates melanocortin receptors in the brain. It has been FDA-approved (as Vyleesi) for the treatment of hypoactive sexual desire disorder in premenopausal women.
Key Research Areas:
• Sexual dysfunction
• Melanocortin pathway
• Central nervous system effects
• Arousal mechanisms
• Hormonal regulation
PT-141 is unique among sexual health treatments as it works through the nervous system rather than the vascular system.
RESEARCH USE ONLY: All products sold on this website are intended for laboratory and research purposes only. These products are NOT intended for human or animal consumption.
